Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines

Area of Science:

• Immunology
• Oncology
• Ophthalmology

Background:

• Uveal melanoma is the most common primary eye cancer in adults.
• Current treatments for primary uveal melanoma do not prevent metastasis or improve survival.
• Metastatic uveal melanoma remains a significant clinical challenge requiring novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of MHC II uveal melanoma cell-based vaccines in activating tumor-reactive CD4+ T cells for immunotherapy.
• To determine if Mel202/DR1/CD80 vaccine cells can directly activate purified, naïve CD4+ T cells.
• To analyze the characteristics of the CD4+ T cell response induced by these novel vaccines.

Main Methods:

• Utilized Mel202/DR1/CD80 uveal melanoma cell-based vaccines.
• Co-cultured vaccine cells with purified, naïve CD4+ T cells.
• Assessed CD4+ T cell proliferation, cytokine secretion (IFNγ, Th1, Th2, Th17), and TCR-Vβ repertoire.
• Analyzed the expression of FoxP3 and ICAM-1 on vaccine cells and their role in T cell activation via LFA-1.

Main Results:

• Mel202/DR1/CD80 vaccine cells directly activated purified CD4+ T cells, leading to proliferation and high IFNγ secretion.
• A polyclonal T cell response was induced, suggesting the potential to target multiple tumor antigens.
• The vaccine induced a regulatory T cell component (FoxP3+) but did not limit the anti-tumor response.
• ICAM-1 expression on vaccine cells was crucial for CD4+ T cell activation through LFA-1 interaction.

Conclusions:

• MHC II uveal melanoma vaccines effectively activate purified CD4+ T cells.
• These vaccines induce a robust and polyclonal T cell response with potential anti-tumor activity.
• Mel202/DR1/CD80 vaccine cells represent a promising novel immunotherapy for uveal melanoma patients.